Biotransformation of a new hypoglycemic agent, N-(p-toluenesulfonyl)-5-methyl-2-pyrazoline-1-carbonamide (SPC-703) in humans and rats.
Over 60% of a dose of N-(p-toluenesulfonyl)-5-methyl-2-pyrazoline-1-carbonamide (SPC-703) given to humans or rats was excreted with urine, one third of the dose was eliminated in unchanged form. From the urine of both species two metabolites of SPC-703, M1 and M2, were isolated and their chemical structures was established. Metabolite M1 is a carboxy- and metabolite M2 a hydroxy derivative of SPC-703.
D000818:Animals; D001711:Biotransformation; D055598:Chemical Phenomena; D002621:Chemistry; D002855:Chromatography, Thin Layer; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism* / Q000652:urine; D008297:Male; D011720:Pyrazoles / Q000378:metabolism / Q000652:urine; D051381:Rats; D013453:Sulfonylurea Compounds / Q000378:metabolism* / Q000652:urine
D007004:Hypoglycemic Agents; D011720:Pyrazoles; D013453:Sulfonylurea Compounds; C009971:glipalamide